{
  "docId": "019de076-aef8-73ee-832d-fdb26bc98608",
  "docSlug": "c95c061ca7ee3d0fc69daa81d5a345ff",
  "documentTitle": "Legend Biotech | Investor Presentation Deck | 14 slides",
  "authorId": "legend-biotech",
  "authorName": "Legend Biotech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 14,
  "prevPage": 13,
  "nextPage": null,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-aef8-73ee-832d-fdb26bc98608/14",
  "deckHref": "/decks/019de076-aef8-73ee-832d-fdb26bc98608",
  "deckJsonHref": "/decks/019de076-aef8-73ee-832d-fdb26bc98608.json",
  "deckAnchorHref": "/decks/019de076-aef8-73ee-832d-fdb26bc98608#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.42,
        "x": 0.5,
        "y": 0.22
      },
      "kind": "list",
      "text": "LONG-TERM GROWTH STRATEGY: Move CARVYKTI to earlier lines of therapy; increase penetration in the US and expand into global markets; Focus on unmet medical needs in hematology/oncology; Develop therapies with transforming potential; Increase accessibility through lower cost and scalable manufacturing; Build a global powerhouse by leveraging external collaborations",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5cbaaeee-71a3-496b-9ca7-a6e17a4bf33a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.42,
        "x": 0.08,
        "y": 0.22
      },
      "kind": "list",
      "text": "NEAR-TERM GOALS: Continue to increase manufacturing capacity and efficiency; Begin manufacturing from Ghent facilities; Complete enrollment of CARTITUDE-5 in 1H24; Ongoing enrollment of CARTITUDE-6; Advance early-stage pipeline programs; Launch lenalidomide refractory 1-3 prior lines indication based on CARTITUDE-4, if approved by regulatory authorities. The PDUFA target action date is April 5, 2024. CHMP opinion, anticipated in 1Q 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6614e40-4af8-443a-93b7-2934d6fef8a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.43,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Outlook: 2024 and Beyond",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "480a1c37-3991-420b-a980-0849f66abd4f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}